Billionaire investor Stanley Druckenmiller's Duquesne Family Office has executed a significant contrarian portfolio shift, fully divesting from high-flying AI stocks Nvidia and Palantir, citing concerns over potential overvaluation and an 'early innings bubble.' Concurrently, Druckenmiller heavily invested in Teva Pharmaceutical Industries, making it his fund's second-largest holding, betting on the drugmaker's turnaround driven by resolved opioid litigation, a strategic pivot to novel drug development, and an improved balance sheet, which he views as attractively valued.
Stanley Druckenmiller's Duquesne Family Office executed a significant contrarian portfolio shift, fully divesting from high-flying AI stocks Nvidia (NVDA) and Palantir Technologies (PLTR) during Q3 2024 and Q3 2024-Q2 2025. This move, involving the sale of 214,060 NVDA shares and 769,965 PLTR shares, was driven by concerns over potential overvaluation and an "early innings bubble" in AI, as evidenced by NVDA's P/S ratio of 31 and PLTR's 152. Concurrently, Duquesne aggressively accumulated 15,968,935 shares of Teva Pharmaceutical Industries (TEVA) over four quarters, making it the fund's second-largest holding. This substantial investment signals strong conviction in Teva's turnaround, which has seen its shares rally 218% since mid-2023. Key catalysts for Teva include the resolution of opioid litigation with a $4.25 billion settlement and a strategic pivot towards higher-margin novel drug development, with Austedo's projected peak sales exceeding $2 billion. Teva's financial health has also improved, with net debt reduced to below $16.6 billion, and its forward P/E of 8.6 suggests attractive valuation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
